The SYBYL-X 2.0 program was used for ligand sketching, hydrogen addition, and minimization with the Trips force field and Gasteriger-Huckel charges. 1 The dopaminergic receptors, D 3 R (PDB code: 3PBL) and D 2 R (PDB code: 6C38), were refined using the Biopolymer module implemented in SYBYL-X 2.0. After the removal of all the ligands and water molecules, the N-and C-termini were treated with charges.
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The SYBYL-X 2.0 program was used for ligand sketching, hydrogen addition, and minimization with the Trips force field and Gasteriger-Huckel charges. 1 The dopaminergic receptors, D 3 R (PDB code: 3PBL) and D 2 R (PDB code: 6C38), were refined using the Biopolymer module implemented in SYBYL-X 2.0. After the removal of all the ligands and water molecules, the N-and C-termini were treated with charges.
Subsequently, hydrogens were added and staged minimizations were performed using AMBER7_FF99 force field and Gasteriger-Marsili charges. The most selective D 3 R ligand among the identified compounds, compound 9i, was docked into the refined D 2 R and D 3 R with the program LeDock (www.lephar.com). 2 Briefly, a rectangular box was generated in the LeDockGUI, a free graphics user interface of VMD, based on the binding pockets of eticlopride in D 3 R and risperidone in D 2 R. The compound 9i was docked into the dopaminergic receptors using LeDock program and for each ligands, 30 poses were generated and clustered by a RMSD cutoff of 1 Å. 
General synthesis of N-phenylpiperazines
To a solution of bis(2-chloroethyl)amine hydrochloride in 1ml diethylene glycol monomethyl ether was added varying substitution anilines, the mixture was allowed to reflux at 130°C for 15 hours. After cooling, 1 mL MeOH was added to reaction mixture followed by addition of 100 mL Et 2 O. The resulting precipitate was filtered and washed with Et 2 O to give corresponding piperazine hydrochloride salts. 4 The salts were directly used in next step without further purification.
1-(4-Chlorophenyl)piperazine (8a)
Compound 8a was obtained as a yellowish solid. Yield: 50%. 1 H NMR (300 MHz, DMSO-d 6 ) δ 9.55 (s, 2H), 7. 34-7.18 (m, 2H), 7.07-6.83 (m, 2H), 3.46-3.29 (m, 4H), 3.17 (s, 4H) .
1-(3-Chlorophenyl)piperazine (8b)
Compound 8b was obtained as a yellowish solid. Yield: 65.3%. 1 H NMR (300 MHz, CDCl 3 ) δ 7.21 (t, J = 8. 1 Hz, 1H), 2H), 1H), 4H) 
1-(2,3-Dichlorophenyl)piperazine (8d)
Compound 8d was obtained as a yellowish solid. Yield: 63.1%. 1 H NMR (300 MHz, CDCl 3 ) δ 7.21-7.04 (m, 2H), 6.95 (dd, J = 5.7, 3.9 Hz, 1H), 3.04 (ddd, J = 12.7, 5.0, 1.8 Hz, 8H).
1-(2,4-Dichlorophenyl)piperazine (8e)
Compound 8e 
1-(3-(Trifluoromethyl)phenyl)piperazine (8f)
Compound 8f was obtained as a yellowish solid. Yield: 61.9%. 1 H NMR (300 MHz, CDCl 3 ) δ 7.41 (t, J = 7.9 Hz, 1H), 7.21 (d, J = 7.7 Hz, 1H), 7.16-7.04 (m, 2H), 3.56 (dd, J = 6.4, 3.8 Hz, 4H), 3.42 (dd, J = 6.4, 3.8 Hz, 4H) .
1-(4-Fluorophenyl)piperazine (8g)
Compound 8g was obtained as yellowish solid. Yield: 75%. 1 H NMR (500 MHz, cd 3 od) δ 7.32 -7.25 (m, 2H), 7.13 -7.04 (m, 2H), 3.61 -3.54 (m, 4H), 3.51 (dd, J = 6.46, 3.47 Hz, 4H).
1-(2-Fluorophenyl)piperazine (8h)
Compound 8h was obtained as yellowish solid. Yield: 87.5%. 1 H NMR (300 MHz, CDCl 3 ) δ 7.11-6.88 (m, 4H), 3.06 (s, 8H). 
1-(2,3-Difluorophenyl)piperazine (8i)

General procedure of N-alkylation
N- phthalimide was added to a suspension of 4-phenylpiperazine, K 2 CO 3 and NaI in acetonitrile. The reaction mixture was allowed to reflux overnight and monitored by TLC (CH 2 Cl 2 /MeOH, 10:1). Upon completion of reaction, K 2 CO 3 was removed by filtration and washed by acetone. The resulting filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography eluting with EtOAc/hexane (1:4→1:3) to furnish target compounds. 62, 153.47, 138.07, 135.84, 132.86, 128.90, 127.18, 121.43, 61.71, 56.73, 52.65, 41.52, 30.37, 27 .40. 4-(3-Chlorophenyl)piperazin-1-yl) 42, 149.29, 133.88, 132.11, 130.58, 128.72, 127.54, 123.57, 123.16, 120.33, 58.02, 53.35, 51.18, 37.85, 26.60, 24 .23.
2-(4-(4-(4-Chlorophenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione (9a)
2-(4-(
2-(4-(4-(2-Chlorophenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione (9c)
Compound 9c 45, 152.33, 134.90, 133.93, 132.11, 129.99, 123.20, 119.15, 115.65, 113.79, 57.96, 53.03, 48.61, 37.83, 26.58, 24 .19.
2-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione (9d)
Compound 9d 1.74 (dt, J = 14.86, 7.47 Hz, 2H), 2H) . 13 C NMR (101 MHz, CDCl 3 ) δ 168. 45, 151.30, 133.98, 133.91, 132.13, 127.42, 124.50, 123.19, 118.58, 57.97, 53.28, 51.30, 37.86, 26.60, 24 .22.
2-(4-(4-(2,4-Dichlorophenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione (9e)
Compound 9e 45, 148.12, 133.92, 132.14, 130.27, 129.42, 128.08, 127.59, 123.19, 121.12, 57.97, 53.25, 51.20, 37.87, 26.60, 24 .22. 4-(3-(Trifluoromethyl)phenyl)piperazin-1-yl) 
2-(4-(
